Actively Recruiting

Phase 3
Age: 18Years - 85Years
All Genders
ID06564818

A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder

Led by Cybin IRL Limited · Updated on 2026-05-06

220

Participants Needed

46

Research Sites

4 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of CYB003, a deuterated psilocin analog, compared to a matching placebo as an additional treatment for people with Major Depressive Disorder (MDD). The study focuses on adults aged 18 to 85 who have moderate to severe depression and have not responded adequately to a stable antidepressant medication. This phase III trial aims to add knowledge about treating MDD by assessing CYB003 alongside current antidepressants and psychological support. Participants are randomly assigned to one of two groups. One group receives 16 mg of CYB003 in two dosing sessions spaced about three weeks apart, while the other group receives a placebo on the same schedule. All participants continue their current antidepressant treatments and receive manualized psychological support throughout the study. Those who do not respond to placebo may join a later extension trial to receive CYB003. Throughout the trial, participants undergo several assessments, including the Montgomery-Åsberg Depression Rating Scale (MADRS) at multiple time points from screening to 42 days after treatment begins. Other evaluations include the Beck Depression Inventory, Clinical Global Impression Scale, Generalized Anxiety Disorder scale, and Quality of Life questionnaire. Participants are monitored for safety, treatment response, and tolerability, with the total study period lasting around six weeks after dosing begins.

CONDITIONS

Brief Title

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 to 85 years inclusive, at Screening
  • Diagnosis of Major Depressive Disorder (single or recurrent episode) as defined by DSM-5 TR
  • Depression of moderate to severe degree at Screening and Baseline
  • Stable dose of a single antidepressant medication for at least one month prior to Screening with inadequate response (less than 50% improvement)
  • Body mass index (BMI) of 40 kg/m2 or less at Screening
  • Able to refrain from nicotine use during dosing sessions (up to 8 hours)
  • Registered with a healthcare professional confirming diagnosis and previous treatments
  • Participants capable of producing sperm must use condom plus spermicide during the trial and for 12 weeks after final dose
  • Participants of childbearing potential must use highly effective contraception plus condom and spermicide during the trial and for 12 weeks after final dose
  • Negative pregnancy test at Screening and Day 1 prior to dosing
  • Female participants capable of producing eggs must use contraception unless postmenopausal or permanently sterile
  • Provided written informed consent including compliance with trial requirements
Not Eligible

You will not qualify if you...

  • Current or previous diagnosis of schizophrenia spectrum or other psychotic disorders, bipolar disorder, or borderline personality disorder
  • ADHD diagnosis if currently taking medication for ADHD
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 in first degree relatives
  • Significant suicide risk within past 6 months or suicidal behaviors within 12 months of Screening
  • Treatment-resistant MDD defined as failure to respond to 2 or more antidepressants of different classes
  • Electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation in last 6 months
  • Current use of monoamine oxidase inhibitors, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, antipsychotics or mood stabilizers for MDD
  • More than 10 lifetime uses or recent use (within 12 months) of psychedelics or 5-HT2a receptor agonists
  • Ketamine or S-ketamine use within 6 months prior to Screening
  • Clinically relevant abnormal physical health interfering with the trial
  • Renal insufficiency
  • Uncontrolled thyroid conditions unless medicated
  • Uncontrolled hypertension, arrhythmia, or abnormal heart rate/blood pressure
  • Conditions interfering with trial medication absorption or metabolism
  • History of organic brain disorders related to seizures
  • Known sensitivity to psilocin or trial medication excipients
  • Use of 5-HTP or St John's Wort within 14 days prior to trial medication
  • Participation in another drug trial with medication within 12 weeks prior to dosing
  • Participants capable of producing sperm unwilling to abstain from sperm donation during and 12 weeks after dosing
  • Pregnant, breastfeeding, planning to conceive, or unwilling to abstain from egg donation during and 12 weeks after dosing
  • History of serotonin syndrome
  • Unwilling to consent to audio and video recording during sessions
  • Staff or family members of Cybin IRL Limited or related organizations

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Approximately 6 weeks

Participants receive two dosing sessions of either CYB003 or placebo approximately three weeks apart, while continuing their current antidepressant medication and receiving psychological support throughout the study.

1 baseline visit and multiple follow-up visits on Days 2, 10, 21, 23, 31, and 42

Trial Site Locations

Total: 46 locations

1

Scottsdale Research Institute

Phoenix, Arizona, United States, 85022

Actively Recruiting

2

Mountain Clinical Trials

Phoenix, Arizona, United States, 85050

Actively Recruiting

3

Noble Clinical Research

Tucson, Arizona, United States, 85704

Actively Recruiting

4

Del Sol Research Management

Tucson, Arizona, United States, 85715

Actively Recruiting

5

CenExel CIT (Clinical Innovations, Inc)

Bellflower, California, United States, 90706

Actively Recruiting

6

Kadima Neuropsychiatry Institute

La Jolla, California, United States, 92037

Actively Recruiting

7

Bespoke Treatment/Lipov Medical Group

Los Angeles, California, United States, 90025

Actively Recruiting

8

Catalina Research Institute

Montclair, California, United States, 91763

Actively Recruiting

9

Excell Research, Inc

Oceanside, California, United States, 92056

Actively Recruiting

10

Open Mind Therapeutics

San Francisco, California, United States, 94114

Actively Recruiting

11

Inland Psychiatric Medical Group Inc

San Juan Capistrano, California, United States, 92675

Actively Recruiting

12

Mountain View Clinical Research

Denver, Colorado, United States, 80209

Actively Recruiting

13

Starlight Clinical Research

Evergreen, Colorado, United States, 80439

Actively Recruiting

14

Research Centers of America

Hollywood, Florida, United States, 33024

Actively Recruiting

15

K2 Medical Research-Maitland

Maitland, Florida, United States, 32751

Actively Recruiting

16

Floridian Neuroscience Institute

Miami, Florida, United States, 33135

Actively Recruiting

17

Segal Trials West Broward

North Miami, Florida, United States, 33161

Actively Recruiting

18

Clinical Neuroscience Solutions, Inc

Orlando, Florida, United States, 32801

Actively Recruiting

19

Charter Research

Orlando, Florida, United States, 32803

Actively Recruiting

20

Combined Research Orlando Phase I-IV

Orlando, Florida, United States, 32807

Actively Recruiting

21

K2 Medical Research - Tampa

Tampa, Florida, United States, 33634

Actively Recruiting

22

Atlanta Center for Medical Research, CenExel

Atlanta, Georgia, United States, 30331

Actively Recruiting

23

CenExel iResearch Atlanta

Decatur, Georgia, United States, 30330

Actively Recruiting

24

CenExel iResearch Savannah

Savannah, Georgia, United States, 31405

Actively Recruiting

25

Great Lakes Clinical Trials, DBA Flourish Research

Chicago, Illinois, United States, 60640

Actively Recruiting

26

Uptown Research Institute

Chicago, Illinois, United States, 60640

Actively Recruiting

27

Psychiatric Medicine Associates, LLC

Skokie, Illinois, United States, 60076

Actively Recruiting

28

Atlas Psychiatric

New Orleans, Louisiana, United States, 70115

Not Yet Recruiting

29

DelRicht Research

New Orleans, Louisiana, United States, 70115

Actively Recruiting

30

Sunstone Medical, PC

Rockville, Maryland, United States, 20850

Actively Recruiting

31

Adams Clinical Boston

Boston, Massachusetts, United States, 02116

Actively Recruiting

32

Adams Clinical

Boston, Massachusetts, United States, 02472

Actively Recruiting

33

Elixia Health

Springfield, Massachusetts, United States, 01103

Actively Recruiting

34

Redbird Research, LLC

Las Vegas, Nevada, United States, 89119

Actively Recruiting

35

Oasis Clinical Trials

Las Vegas, Nevada, United States, 89121

Terminated

36

Global Medical Institutes, Princeton Medical Institute

Princeton, New Jersey, United States, 08540

Actively Recruiting

37

Adams Clinical Harlem

New York, New York, United States, 100029

Actively Recruiting

38

Adams Clinical Bronx

The Bronx, New York, United States, 10461

Actively Recruiting

39

Monroe Biomedical Research

Monroe, North Carolina, United States, 28112

Actively Recruiting

40

Neurobehavioral Clinical Research

North Canton, Ohio, United States, 44720

Actively Recruiting

41

Clinical Neuroscience Solutions, CNS Healthcare

Memphis, Tennessee, United States, 38119

Actively Recruiting

42

InSite Clinical Research, LLC

DeSoto, Texas, United States, 75115

Actively Recruiting

43

Zillan Clinical Research

Houston, Texas, United States, 77433

Actively Recruiting

44

AIM Trials

Plano, Texas, United States, 75093

Withdrawn

45

Cedar Clinical Research

Murray, Utah, United States, 84107

Actively Recruiting

46

Inner Space Research, LLC

Orem, Utah, United States, 84058

Actively Recruiting

Loading map...

Research Team

C

Clinical Development

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Double-blinded, Randomized Placebo-controlled Trial of 40 ...

Major Depressive Disorder

Actively Recruiting

1 location

31P-MRS and Functional Connectivity Study of 5-HTP and Creat...

Major Depressive Disorder

Actively Recruiting

1 location

Phase 2 Study of Oral Zelquistinel (GATE-251) or Placebo for...

Major Depressive Disorder

Actively Recruiting

32 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here